Stefano Boschi

Recommendations on the clinical application and future potential of α-particle therapy

Valentina Di Iorio, Anna Sarnelli, Stefano Boschi, Maddalena Sansovini et autres

This review comprehensively assesses the clinical applications and future potential of alpha-emitting radionuclides available for targeted alpha-particle therapy (TAT) in cancer treatment. The approval of radium-223 therapy in 2013 marked a significant advancement in alpha-emitting therapeutic radiopharmaceuticals, which are primarily used in …

How Regulation 536/2014 Is Changing Academic Research with Therapeutic Radiopharmaceuticals: A Local Experience

Valentina Di Iorio, Stefano Boschi, Erika Brugugnoli, Maddalena Sansovini et autres

Background/Objectives: This report examines the future of academic studies involving investigational therapeutic radiopharmaceuticals within the framework of Regulation (EU) No. 536/2014. It discusses the impact of Good Manufacturing Practice (GMP) requirements (EudraLex-Volume 4-Good Manufacturing Practice guidelines) on the development of radiopharmaceuticals, based …

it (code pays fourni par la source)

Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project

Valentina Di Iorio, Anna Sarnelli, Stefano Boschi, Maddalena Sansovini et autres

This review comprehensively assesses the clinical applications and future potential of alpha-emitting radionuclides available for targeted alpha-particle therapy (TAT) in cancer treatment. The approval of radium-223 therapy in 2013 marked a significant advancement in alpha-emitting therapeutic radiopharmaceuticals, which are primarily used in …

it, ro, gb, si, fr, pl (code pays fourni par la source)

Production and Quality Control of [68Ga]Ga-FAPI-46: Development of an Investigational Medicinal Product Dossier for a Bicentric Clinical Trial

Alessandro Cafaro, Cristina Cuni, Stefano Boschi, Giacomo Foschi et autres

Background/Objectives: Fibroblast activation protein (FAP) is highly expressed in tumor stroma and selected inflammatory conditions, offering a promising target for molecular imaging. [68Ga]Ga-FAPI-46 is a DOTA-based FAP inhibitor with excellent tumor-to-background ratio and potential advantages over [18F]FDG in low-glycolytic tumors. This article …

it (code pays fourni par la source)

Production and Quality Control of [68Ga]Ga-FAPI-46: Development of an Investigational Medicinal Product Dossier for a Bicentric Clinical Trial

Alessandro Cafaro, Cristina Cuni, Stefano Boschi, Giacomo Foschi et autres

Fibroblast activation protein (FAP) is highly expressed in tumor stroma and selected inflammatory conditions, offering a promising target for molecular imaging. [68Ga]Ga-FAPI-46 is a DOTA-based FAP inhibitor with excellent tumor-to-background ratio and potential advantages over [18F]FDG in low-glycolytic tumors. Background/Objectives: This article …

it (code pays fourni par la source)

Recommendations on the Clinical Application and Future Potential of α-Particle Therapy. A Comprehensive Review of the Results from the SECURE Project

Valentina Di Iorio, Anna Sarnelli, Stefano Boschi, Maddalena Sansovini et autres

Background/Objectives The document comprehensively reviews the clinical applications and future potential of alpha-emitting radionuclides available for targeted alpha-particle therapy (TAT) in cancer treatment. The approval of radium-223 (Ra-223) therapy in 2013 marked a significant advancement in alpha-emitting therapeutic radiopharmaceuticals, which are primarily …

it, ro, gb, si, fr, pl (code pays fourni par la source)

Theragnostic: radiopharmaceuticals and nuclear medicine as viewed through Hegel’s eyes

Stefano Boschi, Paolo Castellucci, Cristina Nanni

it (code pays fourni par la source)

Radiopharmaceutical need between the clinic and regulatory agencies: how philosophy could explain 'the road taken'

Stefano Boschi, Sergio Todde

it (code pays fourni par la source)

Production and Quality Control of [177Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials

Valentina Di Iorio, Stefano Boschi, Cristina Cuni, Manuela Monti et autres

Since prostate cancer is the most commonly diagnosed malignancy in men, the theranostic approach has become very attractive since the discovery of urea-based PSMA inhibitors. Different molecules have been synthesized starting from the Glu-urea-Lys scaffold as the pharmacophore and then optimizing the …

it (code pays fourni par la source)

Optimization of Precursor Preparation in PSMA-11 Radiolabeling to Obtain a Highly Reproducible Radiochemical Yield

Antonella Iudicello, Stefano Boschi, Pietro Ghedini, Frank Lohr et autres

[68Ga]Ga-PSMA-11 PET/CT plays a pivotal role in the diagnosis and staging of prostate cancer because of its higher sensitivity and detection rate compared with traditional choline PET/CT. A highly reproducible radiochemical yield of the radiopharmaceutical to be used in the clinical routine …

it (code pays fourni par la source)

From radiotracer to radiopharmaceutical: a philosophical approach

Stefano Boschi, Sergio Todde

it (code pays fourni par la source)

PET radiopharmacy and automation

Stefano Boschi, Sergio Todde

it (code pays fourni par la source)